ArticleBiomedicines2021
Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06158152 (A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Predictive Value of the CRP/Albumin Ratio in Mortality Prediction in Hip Fracture Surgery Patients Admitted to Intensive Care.Life (Basel, Switzerland) · 2026Article
- Anti-biofilm peptides can rescue fluconazole and amphotericin B efficacies against Candida albicans.Scientific reports · 2025Article
- MAFB shapes human monocyte-derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression.JCI insight · 2023Article
- Article
- High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone.Respiratory research · 2022Article
- Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.International journal of molecular sciences · 2022Article
- Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.Journal of personalized medicine · 2022Review
- COVID-19 and Post-Acute COVID-19 Syndrome: From Pathophysiology to Novel Translational Applications.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveTo describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19.
designAn observational, analytical, retrospective cohort study with longitudinal follow-up.
settingHospital Universitario Príncipe de Asturias (HUPA).
participants287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020.
main outcome measuresProfiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (
resultsA statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF.
conclusionsWhen severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient's inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.